The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least FGFR3 testing to help ...

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.

Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...